An Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Recruitment & Eligibility

Status: ot Recruiting

Sex: Not specified

Target Recruitment: 48

Inclusion Criteria

1. Subject's parent or legal guardian has provided written informed
consent/HIPAA authorization prior to any extension study-specific
procedures;
2. Subject has previously completed study VBP15-002 up to and
including the Week 4 Follow-up assessments within 8 weeks prior to
enrollment; and
3. Subject and parent/guardian are willing and able to comply with
scheduled visits, study drug administration plan, and study procedures.
Are the trial subjects under 18? yes
Number of subjects for this age range: 48
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1. Subject had a serious or severe adverse event in study VBP15-002
that, in the opinion of the Investigator, was probably or definitely
related to vamorolone use and precludes safe use of vamorolone for the subject in this study;
2. Subject has current or history of major renal or hepatic impairment, diabetes mellitus or immunosuppression;
3. Subject has current or history of chronic systemic fungal or viral
infections;
4. Subject has used mineralocorticoid receptor agents, such as
spironolactone, eplerenone, canrenone (canrenoate potassium),
prorenone (prorenoate potassium), mexrenone (mexrenoate potassium)
within 4 weeks prior to the first dose of study medication;
5. Subject has evidence of symptomatic cardiomyopathy. [Note:
Asymptomatic cardiac abnormality on investigation would not be
exclusionary];
6. Subject is currently being treated or has received previous treatment with oral glucocorticoids or other immunosuppressive agents. [Notes:
Past transient use of oral glucocorticoids or other oral
immunosuppressive agents for no longer than 3 months cumulative, with last use at least 3 months prior to first dose of study medication, will be considered for eligibility on a case-by-case basis. Inhaled and/or topical corticosteroids prescribed for an indication other than DMD are permitted but must be administered at stable dose for at least 3 months prior to study drug administration];
7. Subject has used idebenone within 4 weeks prior to the first dose of study medication;
8. Subject has an allergy or hypersensitivity to the study medication or to any of its constituents;
9. Subject has severe behavioral or cognitive problems that preclude
participation in the study, in the opinion of the Investigator;
10. Subject has previous or ongoing medical condition, medical history, physical findings or laboratory abnormalities that could affect safety, make it unlikely that treatment and follow-up will be correctly completed or impair the assessment of study results, in the opinion of the Investigator; or
11. Subject is currently taking any investigational drug, or has taken any investigational drug other than vamorolone within 3 months prior to the start of study treatment.
Note: Subjects may be re-evaluated if ineligible due to a transient
condition which would prevent the subject from participating.

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials